The trial, which aimed to replicate and expand an earlier trial, demonstrated pigs infected with ASFV and treated with Seek Labs’ CRISPR-based systems survived longer than untreated infected pigs. Over half of the CRISPR-treated pigs survived beyond the duration of the trial. Observations and data from both studies reveal compelling outcomes where treatment prolonged lifespans of infected pigs compared to control groups.
The new Roden ADA Kit expedites bioanalysis by removing the need for assay development and optimization across molecules to provide robust, reproducible, reliable data from nanoliter sample volumes. This is beneficial when ADA assessment is evaluated in preclinical animal models where sample volume may be limited.
The trial, which aimed to replicate and expand an earlier trial, demonstrated pigs infected with ASFV and treated with Seek Labs’ CRISPR-based systems survived longer than untreated infected pigs. Over half of the CRISPR-treated pigs survived beyond the duration of the trial. Observations and data from both studies reveal compelling outcomes where treatment prolonged lifespans of infected pigs compared to control groups.
The PangenomiX Array is currently the only research solution that combines four assays in one test: SNP genotyping, whole genome copy number variant detection, fixed copy number discovery, blood and HLA typing. The high-throughput array is designed to advance disease risk and detection research, population-scale disease research programs, ancestry and wellness testing, drug efficacy testing, and drug development research.
HELO 2.0 offers a highly flexible and efficient modular hematology solution that is fully scalable with many possible configurations for mid to large-scale laboratories.
This review, which resulted in a Complete Response Letter, was based on the CodeBreaK 200 trial results for the treatment of adults with previously treated locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer. The FDA also issued a new postmarketing requirement for an additional confirmatory study to support full approval that will be completed no later than February 2028.
The Australian patent Office granted patent No. 2019252987 titled 'Cell-Type Specific Exosomes and Use Thereof' for an isolated Exosomes population derived from MSC-NTF cells as well as a pharmaceutical composition for the treatment of neurodegenerative diseases.
GenSci notes the construction of this facility is progressing as planned, and it is expected to be fully operational by 2027, providing a capacity to accommodate up to 2,000 R&D professionals.
Johan Löf, founder and CEO, RaySearch, says: “Further enhancing the capabilities of multi-modality treatments is key for RaySearch in the ambition to provide tools to create the best treatment plans for cancer patients. With RayStation 2024A we also continue with improvements within fast adaptive re-planning, which will be an important focus area during the coming years.”
“After years of experiencing industry challenges firsthand while commercializing gene therapies, I understand the value of strategic partners who are experienced in C> and have supported manufacturers along the challenges commercialization presents,” explained Keren Shani, Executive Director and Head of Cell & Gene Therapy at Trinity Life Sciences. “Trinity launched the C> COE to support clients in a uniquely cross-functional way, so that we can share learnings from our depth of exposure and breadth of experience across client organizations and throughout the lifecycle.”
The VitroGel-Based Cell Invasion Assay Kits solve many of the limitations of animal-based ECM but, most importantly, allow complete control of ECM factors for more accurate and consistent invasion and migration studies. They are powered by VitroGel® hydrogels and the premium quality VitroPrime™ Cell Culture Inserts.
Starting this December, SeekIn's comprehensive range of cancer detection tests, namely OncoSeek, SeekInCare, SeekInCure and SeekInClarity will be distributed by Oncolnv in the following twelve countries: Belgium, Bulgaria, Costa Rica, Egypt, Ghana, Kenya, the Netherlands, Nigeria, Qatar, Singapore, Tanzania and UAE.
By using this website you agree to accept Medical Device News Magazine Privacy Policy
